- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03007147
Imatinib-Mesylat und Kombinationschemotherapie bei der Behandlung von Patienten mit neu diagnostizierter Philadelphia-Chromosom-positiver akuter lymphoblastischer Leukämie
Internationale Phase-3-Studie in Philadelphia Chromosomen-positiver akuter lymphoblastischer Leukämie (Ph+ALL) zum Testen von Imatinib in Kombination mit zwei verschiedenen zytotoxischen Chemotherapie-Rückgraten
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Sonstiges: Laboratory Biomarker Analysis
- Arzneimittel: Cyclophosphamide
- Arzneimittel: Doxorubicin
- Arzneimittel: Vincristine Sulfate
- Sonstiges: Questionnaire Administration
- Arzneimittel: Daunorubicin Hydrochloride
- Arzneimittel: Etoposide
- Arzneimittel: Mercaptopurine
- Arzneimittel: Methylprednisolone
- Arzneimittel: Ifosfamide
- Arzneimittel: Calaspargase Pegol
- Arzneimittel: Leucovorin Calcium
- Arzneimittel: Methotrexate
- Arzneimittel: Cytarabine
- Arzneimittel: Dexamethasone
- Arzneimittel: Dexrazoxane Hydrochloride
- Biologisch: Filgrastim
- Arzneimittel: Imatinib Mesylate
- Arzneimittel: Levoleucovorin
- Arzneimittel: Pegaspargase
- Arzneimittel: Prednisolone
- Arzneimittel: Therapeutic Hydrocortisone
- Arzneimittel: Thioguanine
- Verfahren: Allogeneic Hematopoietic Stem Cell Transplantation
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.
SECONDARY OBJECTIVES:
I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.
III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.
IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.
V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.
VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.
EXPLORATORY OBJECTIVES:
I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.
II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.
III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.
IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.
IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.
IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.
V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.
VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.
VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).
VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.
VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.
X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.
XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.
XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.
OUTLINE:
INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.
INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.
INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.
POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.
ARM A (SR patients assigned to ARM A):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM B (SR PATIENTS ASSIGNED TO ARM B):
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM C (HR PATIENTS):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.
HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.
POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up every year for 3 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australien, 2310
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australien, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6008
- Princess Margaret Hospital for Children
-
Perth, Western Australia, Australien, 6009
- Perth Children's Hospital
-
-
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgien, 3000
- Hospitals Leuven
-
-
-
-
-
Santiago, Chile
- Hospital Roberto del Rio-Universidad de Chile
-
-
-
-
-
Hamburg, Deutschland, 20246
- Universitätsklinik Eppendorf
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Deutschland, 24105
- University Medical Center chleswig- Campus Kiel
-
-
-
-
-
Tampere, Finnland, 33521
- Tampere University Hospital
-
-
-
-
-
Rennes, Frankreich, 35203
- CHU Hopital Sud
-
-
-
-
Kowloon
-
Kowloon Bay, Kowloon, Hongkong
- Hong Kong Children's Hospital
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
-
Monza, Italien, 20900
- Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
-
-
-
-
-
Québec, Kanada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Kanada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Kanada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Kanada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Kanada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 4H4
- Saskatoon Cancer Centre
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Christchurch, Neuseeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Neuseeland, 1145
- Starship Children's Hospital
-
-
-
-
-
Utrecht, Niederlande, 3584 CT
- Princess Máxima Center for Pediatric Oncology
-
-
-
-
-
Caguas, Puerto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
-
-
-
Riyadh, Saudi-Arabien, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
Skåne County
-
Lund, Skåne County, Schweden, 22185
- Skane University Hospital
-
-
-
-
-
Zurich, Schweiz, CH8032
- University Children's Hospital
-
-
-
-
-
Prague, Tschechien, 15018, 5-Motol
- University Hospital Motol
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Vereinigte Staaten, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Vereinigte Staaten, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Vereinigte Staaten, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Vereinigte Staaten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90027
- Children's Hospital Los Angeles
-
Madera, California, Vereinigte Staaten, 93636
- Valley Children's Hospital
-
Oakland, California, Vereinigte Staaten, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Vereinigte Staaten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Vereinigte Staaten, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Vereinigte Staaten, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Nemours Children's Clinic-Jacksonville
-
Loxahatchee Groves, Florida, Vereinigte Staaten, 33470
- Palms West Radiation Therapy
-
Miami, Florida, Vereinigte Staaten, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Vereinigte Staaten, 33176
- Miami Cancer Institute
-
Orlando, Florida, Vereinigte Staaten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Vereinigte Staaten, 32803
- AdventHealth Orlando
-
Orlando, Florida, Vereinigte Staaten, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Sacred Heart Hospital
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Vereinigte Staaten, 33606
- Tampa General Hospital
-
Tampa, Florida, Vereinigte Staaten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Vereinigte Staaten, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Augusta University Medical Center
-
Macon, Georgia, Vereinigte Staaten, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Lurie Children's Hospital-Chicago
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Vereinigte Staaten, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Vereinigte Staaten, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Tufts Children's Hospital
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Children's Hospital of Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, Vereinigte Staaten, 48823
- Michigan State University
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Vereinigte Staaten, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Vereinigte Staaten, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Vereinigte Staaten, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Presbyterian Hospital
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Albany Medical Center
-
Brooklyn, New York, Vereinigte Staaten, 11219
- Maimonides Medical Center
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Vereinigte Staaten, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Hospital
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Vereinigte Staaten, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Vereinigte Staaten, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Vereinigte Staaten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Vereinigte Staaten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Vereinigte Staaten, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Vereinigte Staaten, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Vereinigte Staaten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Vereinigte Staaten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Vereinigte Staaten, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Cook Children's Medical Center
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Vereinigte Staaten, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Vereinigte Staaten, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Vereinigte Staaten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Vereinigte Staaten, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Vereinigte Staaten, 24014
- Carilion Children's
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Vereinigte Staaten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Vereinigte Staaten, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Vienna, Österreich, 1090
- St. Anna Children's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled
- For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
- In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
-
>= 1 year (365 days) and =< 21 years at ALL diagnosis
-
Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
-
ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)
-
Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
-
Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
-
Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
-
ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
-
ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
-
Direct bilirubin =< 2.0 mg/dL
-
Shortening fraction of >= 27% by echocardiogram
-
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
-
Corrected QT interval, QTc < 480 msec
- Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:
- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
-
Known history of chronic myelogenous leukemia (CML)
-
ALL developing after a previous cancer treated with cytotoxic chemotherapy
-
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
-
Down syndrome
-
Pregnancy and breast feeding
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
-
Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
-
Prior treatment with dasatinib, or any TKI other than imatinib
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm A (imatinib mesylate, EsPhALL chemotherapy)
See Detailed Description |
Correlative studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO or IV
Andere Namen:
Given IT
Andere Namen:
Given IV, SC, or IT
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given SC or IV
Andere Namen:
Given PO
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IT
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: Arm B (imatinib mesylate, COG/BFM chemotherapy)
See Detailed Description. |
Correlative studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO or IV
Andere Namen:
Given IT
Andere Namen:
Given IV, SC, or IT
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)
See Detailed Description |
Correlative studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO or IV
Andere Namen:
Given IT
Andere Namen:
Given IV, SC, or IT
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given SC or IV
Andere Namen:
Given PO
Andere Namen:
Given PO or IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IT
Andere Namen:
Given PO
Andere Namen:
Undergo HSCT
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Zeitfenster: Up to 3 years
|
Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone. |
Up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Zeitfenster: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Zeitfenster: Up to 2 years
|
The proportion of patients who receive at least 75% of intended doses. |
Up to 2 years
|
|
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Zeitfenster: Up to 3 years
|
Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events. |
Up to 3 years
|
|
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Zeitfenster: Up to 3 years
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group. |
Up to 3 years
|
|
EFS of all Ph+ patients
Zeitfenster: Up to 3 years
|
Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first. |
Up to 3 years
|
|
Overall survival (OS) of all Ph+ patients
Zeitfenster: Up to 3 years
|
Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause. |
Up to 3 years
|
|
OS of SR Ph+ patients
Zeitfenster: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients |
Up to 3 years
|
|
OS of SR Ph+ patients by randomization group
Zeitfenster: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
OS of high risk Ph+ patients
Zeitfenster: Up to 3 years
|
Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients. |
Up to 3 years
|
|
EFS of all eligibility ABL-class fusion positive ALL patients
Zeitfenster: Up to 3 years
|
Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
|
OS of all eligibility ABL-class fusion positive ALL patients
Zeitfenster: Up to 3 years
|
Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Zeitfenster: Up to 2 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection. |
Up to 2 years
|
|
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Zeitfenster: Up to 3 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm. |
Up to 3 years
|
|
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Zeitfenster: Up to 6 months
|
For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB. |
Up to 6 months
|
|
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Zeitfenster: Up to 3 years
|
The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored. |
Up to 3 years
|
|
MRD assessments made by IGH-TCR PCR assay and NGS assay
Zeitfenster: Up to 3 years
|
Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected. |
Up to 3 years
|
|
IKZF1 deletions alone
Zeitfenster: Up to 3 years
|
Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
IKZF1 deletions with other transcription factor deletions
Zeitfenster: Up to 3 years
|
Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Other identified genetic lesions
Zeitfenster: Up to 3 years
|
Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Frequency of p190 and p210 BCR::ABL1 fusion variants
Zeitfenster: Up to 3 years
|
For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL. |
Up to 3 years
|
|
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Zeitfenster: Up to 2 years
|
Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity. |
Up to 2 years
|
|
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Zeitfenster: Up to 2 years
|
Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity. |
Up to 2 years
|
|
DFS of SR ABL-class fusion positive patients
Zeitfenster: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Secondary and exploratory aims applied to ABL-class fusion positive patients
Zeitfenster: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
Therapeutic impact of major secondary events
Zeitfenster: Up to 3 years
|
Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events. |
Up to 3 years
|
|
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Zeitfenster: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
In vivo activity
Zeitfenster: Up to 3 years
|
Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631. |
Up to 3 years
|
|
Molecular heterogeneity
Zeitfenster: Up to 3 years
|
Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
Cellular heterogeneity
Zeitfenster: Up to 3 years
|
Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
CML-like phenotypes
Zeitfenster: Up to 3 years
|
Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions. |
Up to 3 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lewis B Silverman, Children's Oncology Group
- Hauptermittler: Andrea Biondi, EsPhALL Network/ BFM Study Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Infektionen
- Viruserkrankungen
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- DNA-Virusinfektionen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom, B-Zell
- Lymphom
- Leukämie, lymphatisch
- Leukämie
- Epstein-Barr-Virus-Infektionen
- Herpesviridae-Infektionen
- Tumorvirusinfektionen
- Hämische und lymphatische Krankheiten
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Burkitt-Lymphom
- Vorläufer-T-Zell-lymphoblastisches Leukämie-Lymphom
- Leukämie, biphänotypisch, akut
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Therapeutika
- Chirurgische Eingriffe, operativ
- Nukleinsäuren, Nukleotide und Nukleoside
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Biologische Faktoren
- Kohlenhydrate
- Carboxylsäuren
- Alkaloide
- Podophyllotoxin
- Tetrahydronaphthalene
- Naphthenes
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glucoside
- Glykoside
- Transplantation
- Amides
- Hydrolasen
- Enzyme
- Enzyme und Coenzyme
- Indolen
- Purines
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Steroide, fluoriert
- Benzolderivate
- Sulfonsäuren
- Schwefelsäuren
- Phosphoramid -Senf
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Phosphoramide
- Organophosphorverbindungen
- Nukleoside
- Formyltetrahydrofolate
- Tetrahydrofolate
- Folsäure
- Pterins
- Pteridine
- Interzelluläre Signalpeptide und Proteine
- Schwangerschaften
- Amidohydrolasen
- Vinca -Alkaloide
- Secologanin Tryptaminalkaloide
- Indolalkaloide
- Indolizidine
- Indoliziner
- Arabinonukleosides
- Aminopterin
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Coenzyme
- Glykoproteine
- Glykoconjugate
- Schwangerschaften
- Schwanger
- Zelltransplantation
- Zell- und Gewebe-basierte Therapie
- Biologische Therapie
- 11-Hydroxycorticosteroide
- Hydroxykortikosteroide
- Nebennierenrindehormone
- 17-Hydroxycorticosteroide
- Oxazine
- Säuren, carbocyclisch
- Benzenesulfonaten
- Arylsulfonate
- Arylsulfonsäuren
- Benzoates
- Koloniestimulierende Faktoren
- Hämatopoetische Zellwachstumsfaktoren
- Zytokine
- Benzamide
- Piperazines
- Sulfhydrylverbindungen
- Diketopiperazines
- Imatinibmesylat
- Dexamethason
- Methotrexat
- Prednisolon
- Cyclophosphamid
- Cytarabin
- Etoposid
- Leucovorin
- Levoleucovorin
- Doxorubicin
- Vincristin
- Methylprednisolon
- Daunorubicin
- Hydrocortison
- Asparaginase
- Mercaptopurin
- Dexrazoxan
- Razoxan
- Thioguanin
- Ifosfamid
- Calciumdobesilat
- Stammzelltransplantation
- Dexamethason 21-phosphat
- Granulozyten-Kolonie-stimulierender Faktor
- Filgrastim
- Calaspargase Pegol
- Azathiopurin
- Merphos
- Pegaspargase
- auricularum
- Dexamethasonacetat
- Exifone
- Medrol Veriderm
Andere Studien-ID-Nummern
- AALL1631
- U10CA180886 (US NIH Stipendium/Vertrag)
- 2017 (US NIH Stipendium/Vertrag)
- AALL1631 (Andere Kennung: CTEP)
- NCI-2016-01588 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- 2017-000705-20
- 2024-515499-12-00
- AALL1631 (Andere Kennung: Children's Oncology Group)
- 2017-000705-20 (EudraCT-Nummer)
- 2024-515499-12-00 (Ctis)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .